Table 4 Summary of clinical information.
Cortical encephalitis | MNOS | Cerebral leukodystrophy -like phenotype | Isolated seizures | Aseptic meningitis | |
|---|---|---|---|---|---|
Median age, years | 9.1 | 11 | 5.3 | 10.3 | 4.3 |
Clinical presentation | |||||
Seizures | 88.9 | 92.3 | 42.9 | 100 | 33.3 |
Headache | 72.2 | 76.9 | 42.9 | 0 | 66.7 |
Fever | 61.1 | 38.5 | 28.6 | 0 | 100 |
Motor disorder | 38.9 | 84.6 | 57.1 | 0 | 33.3 |
Cognitive dysfunction | 27.8 | 76.9 | 42.9 | 0 | 33.3 |
Abnormal (psychiatric) behavior | 0 | 84.6 | 0 | 0 | 0 |
consciousness disturbance | 38.9 | 76.9 | 42.9 | 0 | 66.7 |
Sleep disorder | 0 | 61.5 | 0 | 0 | 0 |
CSF WBC increase | 66.7 | 46.2 | 42.9 | 33.3 | 100 |
MRI | Cortical hyperintensities 100 | Supratentorial 100 infratentorial 61.5 | Subcortical white matter 100 | Normal | Non-specificity 66.7 meningeal enhancement33.3 |
Misdiagnosis | Viral Encephalitis62.5 Epilepsy 18.8 Purulent meningitis6.2 Cerebral stroke 6.2 | ON 15.4 CCE 15.4 NMADR-E 15.4 | ADEM 85.7 | Epilepsy 66.7 Viral Encephalitis 33.3 | Purulent meningitis 66.7 Viral Encephalitis 33.3 |
Time to first immunotherapy Median, days | 14 (IQR: 7.5–20) | 15 (IQR: 8–22) | 15 (IQR: 11–22) | / | 19 (IQR: 8–23) |
Type of immunotherapy given | |||||
IVIg+HIMP | 37.5 | 38.5 | 100 | 0 | 66.7 |
IVIg | 18.8 | 7.7 | 0 | 0 | 33.3 |
HIMP | 0 | 7.7 | 0 | 0 | 0 |
Relapse | 68.8 | 84.6 | 50 | 66.7 | 0 |
